Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

Company News Summary

Starpharma Holdings Announces to Commence DEP Cabazitaxel Phase 1/2 Trial

31 Jan 2018  |  11:09:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: Starpharma to commence DEP cabazitaxel phase 1/2 trial

Starpharma Holdings announced that it has received regulatory and ethics approvals to commence its phase 1/2 clinical trial for DEP cabazitaxel. The objectives of the trial are to evaluate the safety, tolerability and pharmacokinetics of DEP cabazitaxel, to define a recommended phase 2 dose (RP2D), and then to determine anti-tumour efficacy of the product in select tumour types. The trial will be conducted at multiple sites, with Guy's Hospital London and University College London Hospital (UCLH) in the UK being the first sites to open for recruitment. Further sites will open and commence recruitment as dose escalation progresses and the phase 2 part of the trial gets underway. 35 patients will be enrolled across the phase 1/2 trial.

Please click here for full details

See more ASX300 News Announcements